Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06686914 · ClinicalTrials.gov registry record · Phase 1
The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex
A Phase 1 study of Driving Performance and Cannabidiol Effects, sponsored by West Virginia University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT06686914: Recruiting Phase 1 study of Driving Performance and Cannabidiol Effects, sponsored by West Virginia University.
NCT06686914 is a Phase 1 study of Driving Performance and Cannabidiol Effects that is actively recruiting participants, run by West Virginia University. The registered enrollment target is 300 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (400% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06686914, a Phase 1 study of Driving Performance and Cannabidiol Effects, is actively recruiting participants, sponsored by West Virginia University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives/purpose of this study are to comprehensively investigate the effects of non-prescription CBD on driving performance, drowsiness, sedation, and cognitive function in a large sample of healthy adults aged 18-30 years, with additional characterization of effects by dose and by sex, using a rigorous RCT design which will naturally mitigate confounding factors.
Primary Outcome
The driving simulator will measure mean standard deviation which is the amount a driver is weaving within the lane during the drive. Ranges from 0 to infinity, with higher means indicating worse performance.
Conditions Studied
Interventions
- DRUG Cannabidiol (CBD) Oil 300mg
- DRUG Cannabidiol (CBD) Oil 150mg
- DRUG Placebo Oil
Study Locations (1)
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2029-05-01 |
| Phase | Phase 1 |
What NCT06686914 shows while recruiting
NCT06686914 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (400% higher).
The record links to 2 conditions, with Driving Performance appearing as the primary indexed condition, and to 3 interventions - of which Cannabidiol (CBD) Oil 300mg is the first listed.
NCT06686914 reports a single indexed study location in West Virginia.
Frequently Asked Questions
What is clinical trial NCT06686914 about?
NCT06686914 is a clinical study titled "The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex". The objectives/purpose of this study are to comprehensively investigate the effects of non-prescription CBD on driving performance, drowsiness, sedation, and cognitive function in a large sample of healthy adults aged 18-30 years, with additional characterization of effects by dose and by sex, using...
What is the current status of trial NCT06686914?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2025-06-30. Estimated completion is 2029-05-01.
What conditions does trial NCT06686914 study?
This clinical trial studies the following conditions: Driving Performance, Cannabidiol Effects.
What interventions are being tested in trial NCT06686914?
The interventions under investigation include: Cannabidiol (CBD) Oil 300mg (DRUG), Cannabidiol (CBD) Oil 150mg (DRUG), Placebo Oil (DRUG).
Who is sponsoring clinical trial NCT06686914?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06686914 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Driving Performance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06686914's enrollment target sits among peer trials
300 124th of 2000 higher than 1,867 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI